Apr 30, 2026
•
1 min read
The next generation of exponential companies will not come from software. It will come from biology.
3 min read
A shift from experimental science to scalable treatment is beginning to reshape where value will emerge in biotech
How Eli Lilly’s GLP-1 boom is driving a second wave of demand across aesthetics and regenerative medicine
A surge in demand is exposing the limits of current treatments and opening the door to a more durable approach
The companies building platforms and infrastructure may capture more value than the therapies themselves
CUTISS is advancing bio-engineered skin through late-stage trials, but the opportunity will depend on data, manufacturing, and eventual pricing
